Medical Device Regulations Changes coming with Brexit.

Listen to this highlight from RCA Radio where Seyed Khorashahi breaks down the UK’s Medical Device Regulations resulting from Brexit and choosing not to join the EU MDR.

 

 

Listen to the entire episode where we go over Brexit and all of the important things happening in the Medical Device industry here.


Looking for help adhering to the New Brexit Regulations? Contact Us Now →


Changes with Brexit

The UK will not be transitioning to the EU MDR or IVDR and will be staying with MDD, AIMD, and IVDD. They plan on making changes in the future as necessary for the UK market.

 

CE Marking

The MHRA will recognize the CE Mark for devices until June 30th, 2023. This applies to products CE marked under the

  • MDD, IVDD, AIMDD, and as well as MDR and IVDR.
  • Class I and General IVD manufacturers can continue to self declare.

 

Conformity Assessment Marking (UK CA)

  • UK Notified Bodies will become UK approved bodies starting January 1st, 2021
  • Device Manufactures can use UK approved bodies for UK CA marking starting on January 1st, 2021
  • UK CA marking will be mandatory on July 1st, 2023

 

MHRA Registration Requirement Dates

 

  • May 1st, 2021
    • Class III medical devices & IVD list A devices
    • Class II b implantable devices
  • September 1st, 2021
    • Class II b non-implantable and II a & IVD list b products
  • September 1st, 2022
    • Class I medical devices and general IVDs

 

UK Responsible Person

Manufactures without a presence in the UK will need a UK responsible person which can be an individual or company similar to EU authorized representative.

 

About RCA

pharmaceutical consultantsRegulatory Compliance Associates® (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:

 

 

We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA-and globally-regulated companies.

 

As your partners, we can negotiate the potential minefield of regulatory compliance and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

 

 

To begin the RCA® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

The US Food and Drug Administration (FDA) has recently expanded on its clarification of a virtual audit, and how new manufacturing protocols in the COVID-19 environment will evolve. Travel constraints continue to impact the industry, especially in countries like India where a tremendous outbreak of COVID cases erupted in April 2021.

 

“This does show that indeed, we are very much interested in doing these remote interactive investigations, you know, especially the ones with video streaming technology.” said Michael Kopcha, director of the Office of Pharmaceutical Quality in the agency’s Center for Drug Evaluation and Research.


Looking for help preparing for the new guidance? Contact Us Now →


After reviewing recommendations from the European Medicines Agency (EMA) and the UK Medicines and Healthcare Regulatory products Agency (UK MHRA), the FDA continues to address the questions many pharmaceutical companies and partners have voiced during the pandemic. FDA officials commented that, due to these early learnings from other global regulatory bodies, they have recently expanded their recommendations for virtual audit best practices and new criteria of considering when to conduct a remote inspection.

 

Two of the initial primary use cases for virtual pharmaceutical inspections mentioned by the FDA include records requests and on-site inspectional work. While developing the new virtual audit process is still ongoing, one recommendation is Pharmaceutical companies should choose a proven regulatory partner to assist with the audit. Agency executives explained they will not be engaging vendors to perform virtual audits on behalf of the FDA.

virtual audit

 

One looming issue to be remedied is will virtual audits be allowed for facilities with serious good manufacturing practice (GMP) violations. FDA officials have expanded on their risk-based approach to prioritization in deciding which sites may qualify. An expanded virtual audit strategy continues to be a work-in-progress by agency officials including defining which companies qualify for an FDA virtual inspection and, more importantly, in what order the virtual audits may happen.

 

GMP violations involve either FDA warning letters or action-indicated site classifications based on the possible corrective actions needed. If the corrective actions needed for a facility can be successfully addressed remotely, it may become more likely that the number of hybrid virtual inspections authorized by the FDA will continue to grow. However, agency official commentary concluded that each facility will be examined by the FDA team on an individual basis with consideration of potential violations involved being a primary decision-making driver.

 

The good news for Pharmaceutical industry executives is it appears the FDA is willing to learn from international regulatory experiences and potentially even collaborate using technology in new ways to increase the FDA’s ability to continue operations. Global travel limitations will more than likely impact every industry for the foreseeable future in 2021 until the COVID-19 vaccine becomes more widely administered.

 

About RCA

pharmaceutical consultantsRegulatory Compliance Associates® (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:

 

 

We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA-and globally-regulated companies.

 

As your partners, we can negotiate the potential minefield of regulatory compliance and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

 

 

To begin the RCA® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

In Vitro Diagnostic Regulation (IVDR) Changes 2021

Listen to this IVDR highlight from RCA Radio where Seyed Khorashahi breaks down the EU’s move from list-based IVD device classifications to a rule-based IVD medical device classification, resulting in four new device classes.
 

 

Listen to the entire episode where we go over all of the important things happening in the Medical Device industry here.


Need help with your transition to the IVDR? Contact Us Now →


Device Classification Changes

  • List-based Classification to a Rule-Based 
    • Class A (lowest risk) to class D (highest risk), where class B, C, and D would require Notified Body (NB) involvement.
  • MDGC 202- 16 Guidance on Classification for in vitro diagnostic Medical Devices under Regulation (EU) 2017/746.

Lifecycle Approach

  • Establishment and Demonstration of effective Quality Management Systems (QMS).
  • More stringent requirements for clinical evidence that demonstrates conformity.
  • Post-Market Performance monitoring and reporting requirements.
  • Introduction of Unique Device Identifiers (UDIs) for improved traceability.

Supply Chain Oversight

  • Regulations covering the entire supply chain.
    • Economic Operators
      • Importers
      • Distributors
      • Authorized Representatives
  • Notified Bodies have discretionary authority to audit suppliers and subcontractors

About Seyed Khorashahi 

Seyed Khorashahi has more than 25 years’ experience leading R&D teams in all aspects of developing safety-critical medical devices. He has held leadership positions at Covidien (Medtronic), Baxter, and Beckman Coulter, Inc., and has an extensive background in medical device product development, quality systems, regulatory affairs, and mergers and acquisitions. Other core competencies include engineering and business strategy.

Seyed has significant domain expertise not only in FDA and EU standards but also in software systems and hardware development for medical devices. A passionate innovator, he is a skilled collaborator as well, with recognized leadership capabilities and a relentless drive to overcome technical and business challenges. He is an influencer, consensus-builder, and a leader with success in establishing and managing relationships with external partners, executives, and internal multi-functional teams.

 

About RCA

pharmaceutical consultantsRegulatory Compliance Associates® (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:

 

 

We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA-and globally-regulated companies.

 

As your partners, we can negotiate the potential minefield of regulatory compliance and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

 

 

To begin the RCA® scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage. 

 

Warszawa, Polska – Regulatory Compliance Associates Inc. (RCA), firma doradcza dla bran±y life science koncentrujqca swoje dziatania na doradztwie jakościowym, prawnym, technicznym, informuje o swojej ekspansji do Europy z nowo otwartym biurem w Polsce – w Warszawie.

 

Regulatory Compliance AssociatesRCA ma swojq siedzibc w USA i oddziaty zlokalizowane w Pleasant Prairie, Wisconsin oraz na potudniowym-wschodzie w pobli±u Tampa na Florydzie. “Wybraliśmy Warszawc na naszq kolejnq lokalizacjc, poniewa± stanowi ona centrum przemystu biotechnologicznego Europy Środkowo-Wschodniej. Dziatalnośá w Polsce daje RCA unikalnq pozycjc dla świadczenia wsparcia firmom bran±y farmaceutycznej, biologicznej i urzqdzeñ medycznych w opracowaniu i wdra±aniu strategii, stu±qcych otrzymaniu zatwierdzeñ na rynku globalnym, w szczególności certyfikatów FDA i Unii Europejskiej” mówi Mitch Januszewski, zato±yciel i dyrektor firmy.

 

Januszewski dodaje: “Jednym z pierwszych dziatañ naszego biura w Warszawie jest udziat w BioForum 2014, konferencji biotechnologicznej dla Europy Centralnej odbywajqcej sic w Iodzi w dniach 28-29 maja 2014 roku. Jesteśmy dumni z bycia sponsorem konferencji, która rozwija spotecznośá life science.”

 

About RCA

 

Regulatory Compliance Associates® Inc. (RCA) provides worldwide services to the following industries for resolution of compliance and regulatory challenges:

 

 

We understand the complexities of running a life science business and possess areas of expertise that include every facet of R&D, operations, regulatory affairs, quality, and manufacturing. We are used to working on the front lines and thriving in the scrutiny of FDA and globally-regulated companies.

 

Regulatory Compliance

 

As your partners, Regulatory Compliance Associates can negotiate the potential minefield of regulatory compliance and private equity due diligence with insight, hindsight, and the clear advantage of our unique expertise and experience.

 

Commitment to Quality

 

Our Certificate of Registration demonstrates that our Quality Management System meets the requirements of ISO 9001:2015, an internationally recognized standard of quality.

Our website uses cookies to give you the best possible experience.

By continuing to use this site, you agree to the use of cookies.
Continue